LONDON – GT Biologics Ltd. is poised to become a pioneer of the new drug class of live biotherapeutics after receiving orphan drug status from the FDA for Thetanix, a bacterial treatment for pediatric Crohn’s disease.
LONDON – Poxel SA generated new patient data on its diabetes treatment Imeglimin, demonstrating it has a novel mechanism of action and showing the drug could be used in combination with existing orally administered Type II diabetes treatments.
LONDON – Pharming Group NV has taken the opportunity to raise €12 million (US$16.2 million) in a private placement after institutional investors started to buy its shares in the market.
HONG KONG – China’s biopharmaceutical industry has been built around hundreds of dedicated zones that enjoy a series of benefits from municipal, provincial and central governments. These biotech parks, often independently managed, seek to attract multiple companies from both China and abroad.
• Kymab Ltd., of Cambridge, UK, said it notified the English Court that it will defend the UK patent proceedings brought by Tarrytown, N.Y.-based Regeneron Pharmaceuticals Inc. in respect of European patent EP1360287. Regeneron initiated the proceedings in September. Kymab said it will defend the UK patent action on the grounds of non-infringement and invalidity of the patent.
LONDON – Immatics Biotechnologies GmbH has closed a €34 million (US$46.1 million) Series D financing, enabling it to complete Phase III development of lead cancer vaccine IMA901 in renal cancer and complete all preparations for filing with the FDA and the European Medicines Agency.
LONDON – Signs of neurodegeneration in a mouse model of Alzheimer’s disease can be halted with a compound that can be taken by mouth, a new study has shown.
LONDON – Astrazeneca plc is taking a giant stride into antibody-drug conjugates (ADCs), acquiring payload technology company Spirogen plc for $200 million in cash, with a further $240 million to come in potential development milestones.
LONDON – Xention Ltd. has taken a major step forward, out-licensing its atrial fibrillation treatment XEN-DO103 in a $163 million-plus joint development agreement in which the UK biotech will retain full rights to the product in the U.S. and Japan.
RSS